- Home
- PMEC vs CUE Comparison
PMEC vs CUE Comparison
Compare PMEC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | CUE |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 49.6M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PMEC | CUE |
|---|---|---|
| Price | $1.06 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 188.8K | ★ 249.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $0.47 |
| 52 Week High | $2.44 | $1.75 |
Technical Indicators
Market Signals| Indicator | PMEC | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 22.60 |
| Support Level | $0.99 | $0.47 |
| Resistance Level | $1.13 | $0.51 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 57.58 | 0.00 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.